Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

Sotera Health reported Q2 2026 net revenues of $321.4M (+9.2% YoY; +8.0% constant currency) and Adjusted EPS of $0.26 (+30% YoY), alongside Adjusted EBITDA up 10.0% (+8.7% constant currency) with Adjusted EBITDA margin expanding to 51.6%. The company raised its FY2026 outlook—net revenues to $1.236B–$1.254B (constant-currency growth 5.25%–6.75%) and Adjusted EBITDA to $634M–$643M (constant-currency growth 5.75%–7.25%). Balance sheet improved with net leverage at 3.0x (vs. 3.2x Dec 2025), $88M operating cash flow in the quarter, and ~$950M available liquidity after refinancing savings of ~$3.5M annual interest expense.

Analysis

The market mechanism here is less about one quarter and more about the equity de-risking from a leveraged, litigation-sensitive situation into a steadier cash-compounding story. With sponsor supply gone and leverage back inside target, SHC should trade more on free-cash-flow durability than on headline revenue growth; that usually matters most when buyers are deciding whether the stock belongs in a special-sits bucket or a quality healthcare infrastructure bucket. If management can show the next 1-2 quarters of cash conversion holding up, the multiple can expand before the numbers need to re-accelerate.

Second-order, the real beneficiaries are the company’s capital structure and its customers, not a broad set of competitors. The competitive moat is regulatory qualification and switching friction, so volume is sticky and pricing tends to lag inflation; that means peers cannot easily undercut without bearing their own capacity and compliance burdens. The loser, if any, is the bear case built around a rapid pricing reset or share loss — those dynamics usually fail when the service is mission-critical and embedded in customer workflows.

The contrarian miss is that some of the margin beat is likely not fully recurring; timing, FX and financing costs helped, while the lowest-quality segment still looks more like a steady contributor than an acceleration story. Over the next 1-3 months the main catalyst is whether the company converts the cleaner balance sheet into stronger guidance confidence and lower perceived legal overhang; over 6-18 months the thesis only works if capex and legal spend do not eat too much of EBITDA. Falsifiers: a renewed step-up in EO-related costs, softer 2H margin commentary, or FCF that fails to de-lever the balance sheet further.

Key Decisions for Investors

• Initiate/ավել existing long SHC on any 1-2 day post-earnings pullback; frame it as a 3-6 month de-risking rerate trade with roughly 10-15% upside if the market starts valuing SHC on cash conversion rather than litigation risk.
• If options liquidity is workable, buy a 6-9 month SHC call spread after implied vol mean-reverts; the point is to capture rerating from balance-sheet cleanup while capping downside if EO/regulatory noise returns.
• Do not short SHC purely on the print; only revisit a bearish stance if next-quarter commentary shows Nelson Labs margin pressure persisting or free cash flow failing to outpace capex by a meaningful margin.
• Set a watch item on 2H guidance credibility at the next investor event; if management does not translate the improved leverage profile into better visibility on debt reduction and litigation normalization, the multiple-expansion case likely stalls.